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Abstract Chronic respiratory infections are a leading global
cause of morbidity and mortality. However, the molecular
triggers that cause respiratory pathogens to adopt persistent
and often untreatable lifestyles during infection remain largely
uncharacterised. Recently, bile aspiration caused by gastro-
oesophageal reflux (GOR) has emerged as a significant com-
plication associated with respiratory disease, and cystic fibro-
sis (CF) in particular. Based on our previous finding that the
physiological concentrations of bile influence respiratory
pathogens towards a chronic lifestyle in vitro, we investigated
the impact of bile aspiration on the lung microbiome of
respiratory patients. Sputum samples (n=25) obtained from
a cohort of paediatric CF patients were profiled for the pres-
ence of bi le acids using high-resolut ion l iquid
chromatography–mass spectrometry (LC-MS). Pyrosequenc-
ing was performed on a set of ten DNA samples that were
isolated from bile aspirating (n=5) and non-bile aspirating
(n=5) patients. Both denaturing gradient gel electrophoresis
(DGGE) and pyrosequencing revealed significantly reduced
biodiversity and richness in the sputum samples from bile
aspirating patients when compared with non-aspirating pa-
tients. Families and genera associated with the pervasive CF
microbiome dominated aspirating patients, while bacteria as-
sociated with the healthy lung were most abundant in non-
aspirating patients. Bile aspiration linked to GOR is emerging
as a major host trigger of chronic bacterial infections. The
markedly reduced biodiversity and increased colonisation by
dominant proteobacterial CF-associated pathogens observed
in the sputum of bile aspirating patients suggest that bile may
play a major role in disease progression in CF and other
respiratory diseases.
Introduction
Chronic respiratory infections associated with lung disease
are a major cause of global morbidity and mortality
(http://who.int/mediacentre/factsheets/fs310/en/). Despite
concerted global research efforts, little progress has been
made in the clinical management of these chronic infections.
Current treatment strategies remain extremely limited,
particularly where chronic pathogens adopt a biofilm
lifestyle. Recent clinical investigations have highlighted bile
aspiration into the lungs as a major consequence of gastro-
oesopheageal reflux (GOR) [1–4]. GOR is routinely detected
in respiratory patients, with incidences as high as 40–80 %
reported for cystic fibrosis (CF) patients [4, 5]. GOR in CF
patients is associated with reduced lung function manifesting
as reduced forced expiratory volume (FEV) and forced vital
capacity (FVC) [6, 7]. However, to date, the mechanism by
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which bile aspiration contributes to reduced pulmonary func-
tion remains unknown. Recently, we have shown that physi-
ologically relevant concentrations of bile cause Pseudomonas
aeruginosa and other respiratory pathogens to adopt a chronic
biofilm lifestyle in vitro [8]. Furthermore, we have also dem-
onstrated that bile acids modulate molecular targets in the
host, suppressing the master regulator of the host hypoxic
and immune response, HIF-1 (Legendre, C., Mooij, M.,
Adams, C. et al., manuscript in revision). This strongly sug-
gests that bile aspiration into the lungs may be a major host
determinant that triggers the establishment of dominant chron-
ic biofilm-forming microbial species.
Several recent reports have highlighted the existence
of a CF microbiome, with distinct microbial profiles
from healthy non-CF patients [9–14]. While the factors
that shape this CF microbiome remain unknown, our
previous studies suggest that bile aspiration may influ-
ence the microbial diversity and, particularly, the emer-
gence of dominant chronic pathogens in CF patients [8].
To investigate this, the bile aspiration status of patients
was established using liquid chromatography–mass spec-
trometry (LC-MS) technology and the lung microbiome
was subsequently investigated using 454 pyrosequenc-
ing. A cohort of paediatric CF patients was recruited for
this study in order to gain insight into the early impact
of bile aspiration on the emergence of chronic infection.
Methods
Patient cohort and ethics statement
Sputum samples (n=25) were collected from paediatric pa-
tients attending the CF clinic at Cork University Hospital,
Ireland, over a 6-month period (Table 1). Ethical approval
was granted for sputum collection and all patients/guardians
signed consent forms for acquisition and analysis outlined in
this study. Sputum specimens were obtained by asking the
patient to cough the specimen into a sterile universal contain-
er. Specimens were labelled with a unique study number. All
sample collection was performed with the research group
blinded to the patient data.
Sample processing
Sample processing was performed using a method adapted
fromTagliacozzi and colleagues [15]. Briefly, sputum samples
were treated with equal volumes of Sputolysin (Calbiochem)
and vortexed for 30 s prior to centrifugation at 5,000 rpm for
15 min. The supernatant was transferred into a sterile contain-
er and 250 μl was removed for bile acid analysis. A 900 μl
aliquot of acetonitrile (Sigma-Aldrich) was added to
each 250 μl sample, which was vortexed for 1 min
and centrifuged at 13,600 rpm for 10 min. A 900 μl
aliquot was transferred to a clean container and the
sample was evaporated under nitrogen to dryness. The
sample was then resuspended in 250 μl MeOH:H2O
(1:1) and subsequently analysed by LC-MS.
LC-MS bile acid analysis
Twelve bile acid standards were used and resuspended in
methanol to a concentration of 20 mM; cholic acid (CA),
chenodeoxycholic acid (CDCA), deoxycholic acid (DCA),
lithocholic acid (LCA), ursodeoxycholic acid (UDCA),
glycodeoxycholic acid (GDCA), taurochenodeoxycholic
acid (TCDCA), taurodeoxycholic acid (TDCA), taurocholic
acid (TCA), glycocholic acid (GCA) and taurolithocholic
acid (TLCA) were purchased from Sigma-Aldrich (Buchs,
Switzerland) and tauroursodeoxycholic acid (TUDCA)
was purchased from Calbiochem (Darmstadt, Germany).
The 12 stock solutions were then pooled together to a
concentration of 100 μM in methanol. All chemicals
used were HPLC grade.
Profiling of the bile composition in the clinical samples
was undertaken using a recently developed LC-MS protocol
(Reen, F.J., Woods, D.F., Zhou, L. et al., manuscript in prep-
aration). Briefly, each sputum sample was analysed for the
presence of 12 principal bile acids compared to purified stan-
dard. Patients were considered bile aspirating where concen-
trations of greater than 1.0 μM were detected. Baseline con-
centrations of less than 0.2 μM bile acids, comparable to
healthy non-CF samples, were considered non-bile aspirating.
Duplicate samples were included in the analysis to ensure
reproducibility and all analyses were performed blinded to
the patient data (Table 1).
Denaturing gradient gel electrophoresis (DGGE) analysis
DNA extraction from the Sputolysin-treated sputum samples
was achieved using the Puregene DNA isolation kit (Qiagen),
according to the manufacturer’s instructions. DNA was
RNase-treated to remove residual RNA and quantified to
100 ng/μl. Bacterial 16S rRNA amplification was performed
using the universal primers 518R and F338GC, while the
fungal internally transcribed region (ITS) was amplified using
the ITS5F and ITS4R universal primers. The following
polymerase chain reaction (PCR) programme was used for
amplification: initial denaturation at 94 °C for 3 min,
followed by 30 (bacterial) or 40 (fungal) cycles of
94 °C for 45 s, 52 °C for 45 s, and 72 °C for 1 min
(bacterial) or 1.5 min (fungal). A final step of 72 °C for
6 min was included. Samples were loaded on a 10 %
(bacterial) or 5 % (fungal) denaturing gel and cluster
analysis of gel images was performed using Phoretix
software (TotalLab, UK).
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16S rRNA pyrosequencing analysis
DNA from Sputolysin-treated samples was quantified and
standardised at a final concentration of 25 ng/μl. Samples
were subsequently sent for 16S rRNA amplification and
high-throughput sequencing using the Roche FLX Genome
Sequencer in combination with Titanium Chemistry at
DNAVision (Belgium). Detailed procedures are provided in
Online Resource 1. Briefly, amplification of the V1–V3 re-
gion was achieved using the universal primers 518R 5′-ATTA
CCGCGGCTGCTGG-3′ and 27F 5′-AGAGTTTGATCCTG
GCTCAG-3′ [16–18]. Amplicons were gel-purified and con-
centrations for all samples were determined by the PicoGreen
assay. A nested PCR approach was taken in light of the low
target DNA abundance of the samples, consistent with previ-
ous reports [19, 20]. Comparison of the biodiversity profiles
from nested and single-step amplification on the same samples
did not reveal any skew or distortion of the taxonomic distri-
bution (data not shown). Between 5,476 and 18,290 raw
sequence reads (Online Resource 2) were obtained from the
nested amplification for each sputum sample (minimum read
length of 430 bp), from which 3,435–11,671 passed QC
analysis (Online Resource 3). Each sequence passing QC
was assigned to a family by the Ribosomal Database Project
(RDP) classifier (v 2.1) with confidence estimate (CE)>80 %
[21]. A minimum of 97 % was assigned at the phyla level,
while more than 95 % of filtered 454 sequences was success-
fully classified down to the genus level. Richness and biodi-
versity indices based on operational taxonomic units (OTUs)
were extracted using the mothur software platform [22]. The
Chao1 index was used for richness estimation, related to the
number of observed OTUs. Biodiversity related to how
Table 1 Patient data for the paediatric patient cohort involved in the microbiome study
ID no. Age (years) Sex IVantibioticsa PO antibioticsa FEV%b Mutation BA (μM)
1 17 M 28 56 90 % ΔF508/ΔF508 0.34
2 15 F 28 14 85 % ΔF508/ΔF508 0.50
3 8 M 0 56 104 % ΔF508/ΔF508 0.50
4 11 M 30 CM+56 days CP 85 % ΔF508/ΔF508 0.16
5 12 M 14 97 % ΔF508/ΔF508 0.28
6 16 M 21 CM+28 days CP 86 % ΔF508/ΔF508 0.1
7 16 M 14 CM 92 % ΔF508/ΔF508 0.27
8 9 M 42 CM 89 % ΔF508/G542 1.16
9 14 M 14 CM 92 % ΔF508/ΔF508 0.53
10 16 F 70 Ma+PO CP 52 % ΔF508/ΔF508 0.11
11 12 F 0 CM 79 % ΔF508/G551D 0.55
12 9 M 65 CM. month on/off MT & AM 42 % ΔF508/ΔF508 1.0
13 14 F SC IVantibiotics CM or CD 30 % ΔF508/ΔF508 14.5
14 9 M 14 42 days 101 % G55ID/Glu56Lys 1.22
15 7 F 42 CM 94 % ΔF508/ΔF508 1.12
16 13 M 0 CM 75 % ΔF508/G551D 0.04
17 13 M 36 CM+PO antibiotics 90 % ΔF508/ΔF508 0.11
18c 11 M 14 CM 118 % G55ID/ΔF508 1.0
19 7 F 14 CM 91 % ΔF508/ΔF508 0.20
20 6 M 0 42 days 94 % ΔF508d 0.18
21 19 M 28 100 days 84 % ΔF508/ΔF508 GORe -ve
22 11 M 28 70 days 91 % ΔF508/ΔF508 GOR -ve
23 15 M 28 0 96 % ΔF508/G551D GOR -ve
24 16 M 14 28 days 72 % ΔF508/ΔF508 0.6
25 8 F 49 42 days 96 % ΔF508/ΔF508 GOR+ve
CD, doxycycline; CM, chronic macrolide; PO, oral antibiotics; SC, semi-continuous
a Number of days in 2012
b Predicted baseline
c Patient commenced ivacaftor treatment
d Heterozygote, second mutation not identified
e Symptom-based classification
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uniformly the sequences are spread into the different observed
OTUs was estimated with the non-parametric Shannon for-
mula. Both indices were evaluated at different distance unit
cutoffs, to test different selectivities in the definition of OTUs.
Statistical analysis
All data were analysed using Prism version 5.0 (GraphPad,
San Diego, CA, USA) for statistical significance. GraphPad
StatMate version 2.00 was used to establish that the study was
adequately powered. Asmicrobiome samples typically exhibit
non-normal distributions, both a non-parametric Mann–Whit-
ney U-test [95 % confidence interval (CI), one tailed] and an
unpaired t-test with Welch correction were applied. Unless
otherwise stated, the Welch corrected t-test is presented and
indicates statistical relevance in both tests. A parametric Stu-
dent’s t-test of unequal variance was performed on the DGGE
data. In all cases, differences <0.05 were considered statisti-
cally significant.
Results
DGGE analysis of bacterial and fungal diversity
in the paediatric CF cohort
To address the hypothesis that bile aspiration significantly
influences the microbiology of the CF lung, DGGE profiling
was performed on a paediatric patient cohort from Cork
University Hospital, Ireland. Bacterial 16S rDNA profiles
were initially analysed from sputum samples taken from nine
patients and were correlated with the clinical classification of
gastro-oesophageal reflux disease (GORD) status (Table 1 and
Online Resource 4). A marked reduction in biodiversity was
evident from those patients whose status was symptomatic for
GORD compared to those who were asymptomatic. While
this suggested that bile aspiration may, indeed, influence the
biodiversity of the CF lung, there is a growing acceptance that
bile aspiration may be asymptomatic and more accurate tech-
nologies are required to measure bile acids in the lungs.
Therefore, in order to evaluate the occurrence and extent of
bile aspiration in our paediatric CF cohort, a protocol for LC-
MS bile acid analysis in sputum was developed (Reen, F.J.,
Woods, D., Zhou, L. et al., manuscript in preparation). Addi-
tional sputum samples were obtained from the paediatric CF
cohort (n=25), from which bacterial and fungal biodiversity
profiles were generated. Patients were classified as either bile
aspirating or non-aspirating on the basis of LC-MS analysis
on sputum (Table 1). DGGE profiles clustered on the basis of
aspiration status with marked reductions in bacterial biodiver-
sity observed in aspirating samples relative to non-aspirating
samples (Fig. 1a). Cluster analysis of fungal biodiversity
profiles was less clear (Fig. 1b), although the paediatric sam-
ples were limited for fungal colonisation, which is unsurpris-
ing given the age profile of the cohort (Table 1). Taken
together, this analysis suggested that bile aspiration into the
lungs of paediatric CF patients had a significant influence on
the microbiology of the lung.
Fig. 1 Denaturing gradient gel electrophoresis (DGGE) analysis of
bacterial and fungal biodiversity in aspirating and non-aspirating paedi-
atric cystic fibrosis (CF) patients. a Patient samples separated into three
distinct clades. The lane numbers refer to the patient ID for comparison of
bacterial profiles. Lane 14# represents a patient that has only recently been
diagnosed with CF and is an outlier to this analysis. Lanes 6* and 10*
represent samples from patients that are symptomatic for gastro-
oesophageal reflux disease (GORD). Statistical analysis was performed
by Student’s t-test. b Fungal biodiversity profiles based on internally
transcribed region (ITS) sequence variation. Lanes 7* and 2*, respective-
ly, represent the GORD-positive outliers described above. The lane
numbers refer to the following patient ID numbers in parentheses: Lane
1 (8), Lane 2 (10), Lane 3 (15), Lane 4 (13), Lane 5 (16), Lane 6 (19),
Lane 7 (6), Lane 8 (12), Lane 9 (18)
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Pyrosequencing biodiversity analysis of the paediatric CF
microbiome: aspirating vs. non-aspirating
In order to characterise the influence of bile aspiration on the
CF microbiome, 454 pyrosequencing (DNAVision, Belgium)
was performed (n=10, Online Resource 5). On the basis of the
sputum bile acid profiling, five bile aspirating and fi non-bile
aspirating samples, matched for age and antibiotic profile,
were selected. Indeed, analysis of the clinical and demograph-
ic data for bile aspirating and non-aspirating patients revealed
no significant difference in FEV%, age or IV antibiotics
between both cohorts (Online Resource 6). However, it should
be noted that two of the lowest FEV% were recorded for
aspirating patients, while one aspirating patient had com-
menced ivacaftor treatment (Table 1). The biodiversity index
of each sample was calculated using the non-parametric Shan-
non algorithm and the bile aspirating samples were found to
have a significantly lower diversity index (p=0.0079) than the
non-bile aspirating samples (Fig. 2a). This was further borne
out by the Chao1 richness index, which was also statistically
significantly reduced (Mann–Whitney p=0.0079) in the bile
aspirating samples (Fig. 2b). This reduction in the biodiversity
index is comparable to previous reports from adult CF patients
when compared with healthy non-CF patients [9, 11, 23]. In
addition to the reduced biodiversity, another distinctive feature
of the aspirating patient samples was the presence of dominant
proteobacterial genera, while non-aspirating patients were
characterised by the abundance of genera more associated
with healthy non-CF lungs (Fig. 2c, d) [9].
Phylum, family and genus level analysis: impact of bile
aspiration
The analysis of biodiversity at the phylum level revealed a
significantly lower relative abundance of Bacteroidetes
(p=0.0135) and Fusobacteriaceae (p=0.0291) in bile aspirat-
ing patients compared to non-aspirating, with the latter phy-
lum being almost entirely absent (Fig. 3a and Online Resource
5). The ratio of Firmicutes to Bacteroidetes, previously shown
to be a marker for the pervasive CF microbiome, was 5.13
(± 4.14) in aspirating patients and 1.11 (± 0.51) in non-
aspirating patients. The analysis of family level diversity
(Fig. 3b and Online Resource 5) revealed lower relative abun-
dance of Veillonellaceae (p=0.0173), Fusobacteriaceae
Fig. 2 Microbiome analysis of bile aspirating and non-aspirating paedi-
atric patients. a Diversity (non-parametric Shannon) and (b) richness
(Chao1) indices from the pyrosequencing dataset. The figures are repre-
sentative of five patient samples for both aspirating and non-aspirating
[Mann–Whitney U-test (p<0.05)]. c Family with the highest relative
abundance in each patient sample. d Combined relative abundance of
Prevotellaceae, Veillonellaceae and Pasteurellaceae in non-aspirating pa-
tients relative to aspirating patients [Student’s t-test (p<0.05)]
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(p=0.04) and Prevotellaceae (p=0.0422) in aspirating sam-
ples. Furthermore, Pasteurellaceae were significantly less
prevalent in aspirating patients (p<0.05).
Genus level analysis (Fig. 3c and Online Resource 5)
revealed the prevalence of dominant proteobacterial spe-
cies in 3/5 of the bile aspirating samples. These genera
(Ralstonia, Pseudomonas and Stenotrophomonas)
accounted for 45–98 % of the total microbiome in these
patients. Additional bile aspirating patients were dominated
by Streptococcus (45 %) and Rothia (43 %). In contrast,
the non-bile aspirating patients contained significantly
higher biodiversity, even where Prevotella was present
at>40 %. Bile aspirating samples were notable for the
almost exclusive absence (with the exception of patient
5, 0.1 % relative abundance) of Haemophilus, which was
present in 4/5 non-aspirating samples. Furthermore, aspi-
rating samples were also characterised by a lower relative
abundance of Veillonella (p=0.0123), Prevotella (p=
0.0462), Fusobacteria (p=0.0391) and Leptotrichia (p=
0.0426) in these patients. Taken together, these data indi-
cate a strong correlation between the aspiration of bile
acids and the prevalence of CF-associated pathogens in
the paediatric lung.
Discussion
Several recent studies have investigated the lung microbiome
in a broad spectrum of respiratory diseases. Despite differ-
ences in experimental design, e.g. sequencing technology and
specimen type, there is strong concordance among the reports
[9, 10, 20, 24–26]. Contrary to the perceived sterility of the
healthy lung, microbial communities that may contribute to
disease have been identified [9], while respiratory conditions
such as CF, chronic obstructive pulmonary disease (COPD)
and asthma were found to have distinct lung microbial pro-
files, both from each other and from the healthy lung [9, 10,
27]. A pattern emerging from these reports is the com-
plexity of the microbial communities that exist in the
different infection niches, leading to a re-evaluation of
organisms that have traditionally been regarded as com-
mensals. There is growing evidence that the diversity of
these profiles may play a previously unforseen role in
disease progression, in tandem with the well-studied
pathogens such as P. aeruginosa, H. influenzae and
S. aureus [9, 10, 13, 14].
Having established the profile of bile aspirating and non-
aspirating patients within our CF cohort, the microbiome from
Fig. 3 a Phylum, b family and c genus level analysis of the paediatric
microbiome in aspirating and non-aspirating patients. In all cases, aspi-
rating samples are represented by the inner circle, while non-aspirating
samples are represented by the outer circle. Relative abundances≥1% are
presented. d The relative abundance of genera was not linear relative to
the patient number (R2=0.4521), with Ralstonia, Rothia, Streptococcus
and Prevotella being over-represented compared to other genera
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these distinct patient groups was analysed. The suitabil-
ity of sputum for this research has previously been
established by several independent studies [9, 10, 28],
which have shown that it reflects a microbiome distinct
from the oropharyngeal tract and consistent with that of
explanted lungs. Furthermore, recent bronchoalveolar
lavage (BAL) data from Aseeri and colleagues confirms
the presence of bile acids in the lower respiratory tract
[1]. A key characteristic of the previously established
CF microbiome is the markedly reduced biodiversity
compared to non-CF samples, often correlating with
the emergence of dominant pathogenic species within
the lung. Our analysis shows that the bile aspirating
patients exhibit markedly reduced biodiversity compared
to non-aspirating patients, mirroring the outcome of the
recent CF vs. non-CF microbiome studies (Fig. 2). Fur-
thermore, in three of the aspirating samples, the reduced
biodiversity correlated with the presence of a single
dominant proteobacterial genus. This is particularly
interesting and is consistent with our hypothesis
that bile aspiration triggers the emergence of chronic-
behaving dominant organisms that ultimately cause the
chronic destruction of the lung [8].
Consistent with previous microbiome studies, the microbi-
al profiles were quite diverse within the CF cohort [9]. Mi-
crobial families that were found to be more prevalent among
CF patients, e.g. Pseudomonadaceae and Aerococcaceae
[9, 13], were only present at relative abundances >1.0 %
in bile aspirating patients. Conversely, Prevotellaceae,
Veillonellaceae, Fusobacteriaceae and Leptotrichiaceae,
which are more prevalent in healthy non-CF patients [9,
13], were significantly more abundant in non-aspirating
patients. The apparent suppression of genera that require
anaerobic conditions for growth, such as Veillonella and
Prevotella, is highly significant, given that previous studies
have shown that almost half of the cultured CF airway
microbial community in adult sputum is composed of
obligate anaerobes [13]. Furthermore, several studies have
shown that the administration of antibiotic regimens
targeting aerobic pathogens does not appear to significant-
ly alter the anaerobic microflora in CF patients [29, 30]. It
is interesting, therefore, to speculate that the reduction of
anaerobic bacteria in aspirating patients may arise as a
consequence of the emergence of dominant proteobacterial
pathogens, particularly in light of our recent finding that
bile causes respiratory pathogens to adopt a chronic life-
style [8]. Alternatively, anaerobic bacteria may be more
sensitive to bile acids, and this will need to be followed
up by future in vitro studies.
The possibility that antibiotic treatment is responsible
for the lower biodiversity in aspirating patients was
considered but is not supported by the evidence. The
antibiotic regimens of all ten patients included in this
study were comparable, although the non-aspirating
samples underwent, on average, a shorter period of IV
antibiotic treatment (Table 1 and Online Resource 6).
Furthermore, given that most CF patients undergo
prolonged antibiotic treatments, the administration of
additional antibiotics during exacerbation are not likely
to cause significant changes in the microbial community
structure [9]. Also, importantly, the consistency of the
replicates included in the study, which were taken at
least 2 months apart (Online Resource 4 and Fig. 1),
strongly supports the hypothesis that bile aspiration is a
major influence on microbial biodiversity in the CF
lung.
This study provides strong evidence that bile aspira-
tion is a major factor in shaping the CF microbiome,
from an early stage in paediatric patients. While consis-
tent with the influence of bile on the chronic behaviour
of respiratory pathogens [8], further studies will be
required on a larger patient cohort to establish whether
the association between bile aspiration and reduced mi-
crobial biodiversity is causative or correlative. Further
analysis of co-morbidities associated with GORD, such
as gastrointestinal disease and chronic cough, will be
undertaken, while the integration of BAL samples into
the analysis will provide additional confirmation of the
response in the lower respiratory tract. It is important to
note that, while the current study focused on CF pa-
tients, the problems associated with bile aspiration are
far more widespread in respiratory disease. The aspira-
tion of bile acids has been confirmed in sputum and
BAL samples from patients suffering from a range of
other respiratory diseases, including COPD and asthma,
and following lung transplantation [31, 32]. Studies
have also found a significant correlation between GOR
and P. aeruginosa infection [33, 34], as well as reduced
lung function in CF and other respiratory patients fol-
lowing lung transplantation [35, 36]. Current treatment
strategies for the management of GOR may not be
effective in preventing the subsequent influence on the
respiratory microbiome. The most effective solution for
the prevention of GOR and bile aspiration is surgery,
specifically Nissen fundoplication, although the high
risks associated with this approach highlight the need
for alternatives. Therefore, alternative innovative thera-
peutic strategies will be required in order to target the
link between this key host trigger and the onset of
chronic infection. This highlights the need for a large-
scale study of bile aspiration in paediatric patients with
CF and other respiratory conditions, with the specific
aim of characterising the influence of bile aspiration on
the microbiology of the lung and elucidating the molec-
ular mechanisms underpinning changes in the microbial
community structure.
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